End-of-day quote
Korea S.E.
03:30:00 13/06/2024 am IST
|
5-day change
|
1st Jan Change
|
15,990
KRW
|
-1.30%
|
|
-6.16%
|
-28.78%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
25,17,196
|
6,60,678
|
5,19,865
|
5,16,197
|
Enterprise Value (EV)
1 |
24,98,632
|
6,33,590
|
4,99,579
|
4,66,512
|
P/E ratio
|
-238
x
|
-115
x
|
-63.5
x
|
-42.9
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
37,61,46,10,750
x
|
EV / Revenue
|
-
|
-
|
-
|
33,99,41,30,725
x
|
EV / EBITDA
|
-614
x
|
-112
x
|
-63.2
x
|
-42
x
|
EV / FCF
|
-1,09,04,36,166
x
|
-9,84,74,937
x
|
-10,74,28,625
x
|
-6,60,35,574
x
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
36.3
x
|
22
x
|
22.3
x
|
6.17
x
|
Nbr of stocks (in thousands)
|
18,055
|
18,268
|
18,268
|
22,993
|
Reference price
2 |
1,39,417
|
36,167
|
28,458
|
22,450
|
Announcement Date
|
01/03/21
|
01/03/22
|
01/03/23
|
29/02/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
13.72
|
EBITDA
1 |
-2,392
|
-3,826
|
-4,070
|
-5,647
|
-7,901
|
-11,107
|
EBIT
1 |
-2,422
|
-4,011
|
-4,255
|
-5,904
|
-8,213
|
-11,507
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-83,851.26%
|
Earnings before Tax (EBT)
1 |
-6,448
|
-1,254
|
-3,984
|
-4,763
|
-6,825
|
-10,274
|
Net income
1 |
-6,448
|
-1,254
|
-3,984
|
-4,763
|
-6,825
|
-10,274
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-74,865.84%
|
EPS
2 |
-1,819
|
-286.0
|
-585.5
|
-315.2
|
-448.3
|
-523.8
|
Free Cash Flow
|
-
|
-15,205
|
-2,291
|
-6,434
|
-4,650
|
-7,065
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-51,478.51%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
31/12/19
|
29/02/20
|
01/03/21
|
01/03/22
|
01/03/23
|
29/02/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
2,541
|
7,611
|
18,563
|
27,088
|
20,287
|
49,685
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-15,205
|
-2,291
|
-6,434
|
-4,650
|
-7,065
|
ROE (net income / shareholders' equity)
|
-
|
-987%
|
-18.2%
|
-14.7%
|
-25.6%
|
-19.2%
|
ROA (Net income/ Total Assets)
|
-
|
-22.5%
|
-11.7%
|
-11.1%
|
-18.5%
|
-13.2%
|
Assets
1 |
-
|
5,575
|
34,108
|
43,093
|
36,858
|
77,959
|
Book Value Per Share
2 |
-3,440
|
2,069
|
3,840
|
1,647
|
1,277
|
3,636
|
Cash Flow per Share
2 |
1,254
|
929.0
|
1,097
|
126.0
|
21.30
|
394.0
|
Capex
1 |
465
|
822
|
26.9
|
2,124
|
167
|
166
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
1,208.17%
|
Announcement Date
|
31/12/19
|
29/02/20
|
01/03/21
|
01/03/22
|
01/03/23
|
29/02/24
|
|
1st Jan change
|
Capi.
|
---|
| -28.78% | 27Cr | | +17.73% | 12TCr | | +16.88% | 11TCr | | -9.04% | 2.32TCr | | +4.40% | 2.29TCr | | -38.15% | 1.74TCr | | -7.75% | 1.74TCr | | -15.36% | 1.69TCr | | +3.42% | 1.37TCr | | +29.63% | 1.18TCr |
Bio Therapeutic Drugs
|